Efalizumab Lifts Quality of Life in Just Two Weeks

Winston-Salem, N.C. - After subcutaneous treatment with efalizumab(Raptiva), patients who achieved 50 to 75 percent improvement in PsoriasisArea and Severity Index (PASI) score reported improvement in quality oflife.

Related Videos
Related Content

Discovering Dermatology Times: March 2023

March 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

New Technology to Assist in Practice Management

March 30th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Pointers With Portela: Sun Damage Repair Products

March 29th 2023

EON Gains FDA Clearance for Back and Thighs

March 29th 2023

Discovering Dermatology Times: March 2023

March 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

New Technology to Assist in Practice Management

March 30th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Pointers With Portela: Sun Damage Repair Products

March 29th 2023

EON Gains FDA Clearance for Back and Thighs

March 29th 2023

Discovering Dermatology Times: March 2023

March 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

New Technology to Assist in Practice Management

March 30th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Pointers With Portela: Sun Damage Repair Products

March 29th 2023

EON Gains FDA Clearance for Back and Thighs

March 29th 2023
© 2023 MJH Life Sciences

All rights reserved.